Jack Jacobs Joins Luventix Advisory Board
Luventix, a leading innovator in Intelligent Disease Diagnostics, is honored to announce that Jack Jacobs has joined its Advisory Board.
Jack Jacobs brings a distinguished background in investment banking, business operations, and military service. Following his military retirement, Jack embarked on a successful career in finance, founding and serving as Chief Operating Officer of Auto Finance Group, Inc., a company specializing in the securitization of debt instruments. Under his leadership, the company was successfully acquired by KeyBank. He later served as Managing Director at Bankers Trust, where he oversaw foreign exchange options and played a key role in the institutional hedge fund business.
Currently, Jack is a principal in The Fitzroy Group, an investment and residential real estate development firm based in London. In addition to his business ventures, he serves on the board of directors for several smaller corporations, which included Resonant (RESN), bringing his extensive strategic expertise and leadership to various organizations. In addition to his business acumen, Jack remains actively involved in military-related initiatives. He is a member of the board of the National Medal of Honor Museum and teaches both finance and politics at the U.S. Military Academy at West Point.
"We are delighted to welcome Jack Jacobs to our Advisory Board," said George Holmes, CEO of Luventix. "His extensive experience in finance, leadership, and strategic planning will provide invaluable insights as we continue to innovate and expand our impact in the diagnostics field."
About Luventix:
Luventix is a medical diagnostics company utilizing a simple, non-invasive urine test to detect and diagnose diseases through metabolomics modeling. By leveraging proprietary advanced machine learning (ML) modeling techniques, Luventix has the unique ability to analyze data and pinpoint disease-specific signatures within a Digital Twin, bridging the gap between diagnostics and therapeutics, revolutionizing clinical trial recruitment, and enabling companion diagnostics as an integral endpoint.
With a commitment to innovation, collaboration, and excellence, Luventix is redefining industry standards and making a meaningful impact on healthcare outcomes. By combining cutting-edge technology with strategic partnerships, Luventix aims to transform the landscape of personalized medicine and accelerate the delivery of life-changing solutions. For more information, please visit www.luventix.com.
Media Contact:
